Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23567470 | 1.00 | PRMT1 (0.63) | PRMT1ADRA1AHDAC3HDAC4HDAC1 | |
| SCHEMBL23567380 | 1.00 | PRMT1 (0.63) | PRMT1ADRA1AHDAC3HDAC4HDAC1 | |
| SCHEMBL10897119 | 0.98 | PRMT1 (0.59) | PRMT1ADRA1AHDAC3HDAC4HDAC1 | |
| SCHEMBL8735106 | 0.91 | ATM (0.52) | PRMT1ADRA1AHDAC3HDAC4HDAC1 | |
| SCHEMBL16853228 | 0.87 | ALDH1A1 (0.59) | PRMT1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16853226 | 0.87 | ALDH1A1 (0.59) | PRMT1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16853231 | 0.87 | ALDH1A1 (0.59) | PRMT1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL23475919 | 0.87 | ALDH1A1 (0.59) | PRMT1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16853225 | 0.87 | ALDH1A1 (0.59) | PRMT1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16853230 | 0.87 | ALDH1A1 (0.59) | PRMT1HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385013-B2 | Micro/nano materials, products obtained by covalently modifying surface of micro/nano materials with hydrophilic materials, and method for making same | CHONGQING BOLANYING (BLY) BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-20 | — | — | US | claimed |
| EP-3470443-A1 | MICRO/NANOMATERIAL, PRODUCT THEREOF WITH SURFACE COVALENTLY MODIFIED WITH HYDROPHILIC MATERIAL, AND MANUFACTURING METHOD | Chongqing Bolanying (BLY) Biotechnology Co., Ltd., China (CN) | 2019-04-17 | — | — | EP | claimed |
| US-20190077746-A1 | MICRO/NANO MATERIALS, PRODUCTS OBTAINED BY COVALENTLY MODIFYING SURFACE OF MICRO/NANO MATERIALS WITH HYDROPHILIC MATERIALS, AND METHOD FOR MAKING SAME | CHONGQING BOLANYING (BLY) BIOTECHNOLOGY CO., LTD. (CN) | 2019-03-14 | — | — | US | claimed |
| WO-2001046127-A1 | ACYL PSEUDOPEPTIDES BEARING A FUNCTIONALISED AUXILIARY SPACER | OM PHARMA (CH) | 2001-06-28 | — | — | WO | claimed |
| EP-0467700-A2 | Coconjugate vaccines comprising immunogenic protein, HIV related peptides, and anionic moieties | MERCK & CO. INC. (US) | 1992-01-22 | — | — | EP | claimed |
| EP-4661912-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATE | Pinotbio, Inc. (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20240293569-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATE | PINOTBIO, INC. (KR) | 2024-09-05 | — | — | US | disclosed |
| WO-2024166056-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATE | PINOTBIO, INC. (KR) | 2024-08-15 | — | — | WO | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2024-02-22 | — | — | US | disclosed |
| US-5606047-A | INCLUDES POLYNUCLEOTIDE DUPLEXES THAT HAVE SIGNIFICANT BINDING ACTIVITY FOR LUPUS ANTIBODIES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5606030-A | IMMUNOGENIC PROTEINS; USEFUL FOR INDUCING ANTI-PEPTIDE IMMUNE RESPONSES IN MAMMALS, HIV-NEUTRALIZING ANTIBODIES IN MAMMALS AND FORMULATING VACCINES TO PREVENT HIV INFECTIONS | MERCK & CO., INC. (US) | 1997-02-25 | — | — | US | disclosed |
| US-5552391-A | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0722318-A1 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | LA JOLLA PHARMACEUTICAL (US) | 1996-07-24 | — | — | EP | disclosed |
| WO-1995007073-A1 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1995-03-16 | — | — | WO | disclosed |
| EP-0642798-A2 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY (CA) | 1995-03-15 | — | — | EP | disclosed |
| EP-0467700-A2 | Coconjugate vaccines comprising immunogenic protein, HIV related peptides, and anionic moieties | MERCK & CO. INC. (US) | 1992-01-22 | — | — | EP | disclosed |
| US-4897444-A | Immobilized fluorogenic substrates for enzymes; and processes for their preparation | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 1990-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | PRMT1 2993/4885ADRA1A 4188/4885HDAC3 1989/4885 |
| US-20240293569-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATE | BCR, IGSF11, STT3B | PRMT1 3185/4885ADRA1A 4395/4885HDAC3 865/4885 |
| US-20190077746-A1 | MICRO/NANO MATERIALS, PRODUCTS OBTAINED BY COVALENTLY MODIFYING SURFACE OF MICRO/NANO MATERIALS WITH HYDROPHILIC MATERIALS, AND METHOD FOR MAKING SAME | PHOSPHO1, PTMS, PAM | PRMT1 481/4885ADRA1A 2899/4885HDAC3 967/4885 |
| US-10385013-B2 | Micro/nano materials, products obtained by covalently modifying surface of micro/nano materials with hydrophilic materials, and method for making same | PHOSPHO1, PTMS, PAM | PRMT1 481/4885ADRA1A 2899/4885HDAC3 967/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | PRMT1 3436/4885ADRA1A 4834/4885HDAC3 1432/4885 |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | PRMT1 3436/4885ADRA1A 4834/4885HDAC3 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.